10X Genomics has started shipping its hotly tipped long-read sequencing technology, GemCode Platform. And the first batch of buyers of the $75,000 machines includes some big names, with the Broad Institute among the organizations to already have a GemCode Platform installed.
A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.
GVK BioSciences, an Indian CRO under fire from European regulators, has signed a deal with Australia's Akaal Pharma to help the company move its in-development psoriasis treatment into mid-stage trials.
PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.
Switzerland-based Actelion is jumping into the vaccines industry by creating Vaxxilon, a startup that will focus on synthetic carbohydrate vaccines. It has licensed exclusive rights to multiple preclinical vaccines and other technologies from the Max Planck Society and will invest up to €30 million ($33 million), which will come in tranches over three to four years.
CRO BioClinica has opened new outposts in the U.K. and Germany, expanding its European footprint and scaling up its capabilities in medical imaging.
More than a year after announcing plans to spin out its drug business, Baxter has begotten Baxalta, a $6 billion standalone company with plans to elbow its way into the upper ranks of biopharma.
Royal Philips and Teva Pharmaceutical Industries are getting the ball rolling on their new med tech incubator in Israel, sinking funds into two startups and planning more investments in the months ahead.
Xenon Pharmaceuticals' Teva-partnered treatment for osteoarthritis pain missed its goals in a Phase IIb trial, a failure the biotech believes won't derail the drug's development in other indications.
Illumina is laying out plans for expansion, signing a 20-year lease on a 155,000-square-foot facility in Cambridge, England.